177Lu-PSMA-617 trials for Prostate cancer

All 177Lu-PSMA-617 trials · All Prostate cancer trials

Phase breakdown

Recruiting trials studying 177Lu-PSMA-617 for Prostate cancer

• 177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer
  NCT07145177 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · 1 location
• A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer
  NCT06320067 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 18 locations
• Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer
  NCT05766371 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 1 location
• Personalized vs. Fixed-Activity 177Lu-PSMA-617 Radiopharmaceutical Therapy (PRODIGY-2)
  NCT06943495 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · 1 location
• Phase I Study of 225Ac-J591 Plus 177Lu-PSMA Small Molecule for Progressive Metastatic Castration Resistant Prostate Cancer
  NCT04886986 · Phase: Phase 1 · Ages: 18 Years to 99 Years · Sex: Male · 2 locations
• SPECT Imaging for Pharmacokinetics and dosimEtry Towards TREATment Optimization
  NCT06389097 · Phase: Not specified · Ages: 18 Years to 100 Years · Sex: All (male and female) · 1 location

Common questions

How many trials study 177Lu-PSMA-617 for Prostate cancer?

6 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.